Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma
Clinical trial NCT05973903 · WITHDRAWN
Trial details
- NCT number
- NCT05973903
- Sponsor
- Tel Aviv Medical Center
- Status
- WITHDRAWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-01
- Primary completion
- 2026-10-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.